제테마

216080KOSDAQ

61.8 / 100

Reference Date: 2026-09-08

Financial Score14.5 / 40

News Sentiment21.3 / 25

Momentum14.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Surged 51.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jetema develops and manufactures biopharmaceuticals based on hyaluronic acid fillers and botulinum toxin, as well as tissue sutures and lifting threads, expanding into both aesthetic and therapeutic markets. Key products like Jetema Dermal Toxin, which received domestic approval in 2024, are driving growth, with global expansion accelerated through licensing agreements with partners in Brazil, China, and Thailand.

Number of Employees

244people

Average Salary

4.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

3.77Industry Average 1.200.0Point

3.1x industry avg (risky)

ROE

-10.91Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

92.88Industry Average 100.004.0Point

In line with industry avg

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲24.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.1% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
제테마, 산업부 바이오헬스 과제 최종 선정…인간콜라겐 의료기기 개...
제테마가 바이오헬스 분야 연구개발 사업에 최종 선정되어 인간콜라겐 기반 의료기기 개발에 진출함으로써 긍정적인 시장 반응을 기대할 수 있다.
Positive
제테마 中 보톡스 5520억 잭팟 가시권…“4400억은 확약 물량”
제테마의 중국 보툴리눔 톡신 허가 신청 완료로 대규모 공급계약 매출 인식이 확실해져 긍정적 전망.
Positive
제테마, 中 보툴리눔 톡신 허가 신청…5520억 공급계약 실적화 ‘첫발...
제테마가 중국에서 보툴리눔 톡신 허가 신청을 통해 신규 시장 진출의 긍정적 첫걸음을 내딛었다.

Detailed Momentum

52-week position3.0Point

52w lower range (36%)

Current 6,580Won52-week high 10,89052-week low 4,050

1-month return6.0Point

1m +51.26% (strong rise)

Volume trend5.0Point

Volume flat

Detailed Disclosure

17 totalPositive 1Neutral 16Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-09-04
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-04
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-04
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-01